MethylGene Gets Beta-Lactamase Inhibitor Program Back From Merck

Other companies have expressed interest in the antibiotic resistance program, MethylGene CEO tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet